We are live on ! Find out more
SRDX

Surmodics

Delisted

SRDX was delisted on the 18th of November, 2025.

114 hedge funds and large institutions have $317M invested in Surmodics in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 36 increasing their positions, 46 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

16% more capital invested

Capital invested by funds: $274M → $317M (+$43.1M)

3% more funds holding

Funds holding: 111114 (+3)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1.02% less ownership

Funds ownership: 85.75%84.73% (-1%)

22% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 46

32% less call options, than puts

Call options by funds: $395K | Put options by funds: $581K

Holders
114
Holders Change
+3
Holders Change %
+2.7%
% of All Funds
2.83%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
36
Reduced
46
Closed
8
Calls
$395K
Puts
$581K
Net Calls
-$186K
Net Calls Change
+$187K

SRDX Hedge Fund Activity: Q2 2017 in Review

114 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Surmodics (SRDX) for Q2 2017, worth a combined $317M — up 16% from $274M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new SRDX positions and 8 closed out — a net gain of 3 holders — while 36 added to existing stakes and 46 trimmed.

The largest buyer was Trigran Investments, adding an estimated $4.54M. The largest seller was JP Morgan Chase, cutting an estimated $4.34M.

  • 114 institutional investors held Surmodics (SRDX) as of Q2 2017, up from 111 in Q1 2017.
  • Funds reported $317M of Surmodics stock for Q2 2017, up 16% quarter-over-quarter.
  • 11 funds opened new Surmodics positions in Q2 2017 and 8 closed out, a net change of +3 holders.
  • The largest Surmodics buyer in Q2 2017 was Trigran Investments, an estimated $4.54M added.
  • The largest Surmodics seller in Q2 2017 was JP Morgan Chase, an estimated $4.34M sold.

Based on aggregated 13F filings for Q2 2017.